-
公开(公告)号：US09695192B2
公开(公告)日：2017-07-04
申请号：US14630519
申请日：2015-02-24
Applicant: GILEAD SCIENCES, INC.
Inventor： Britton Kenneth Corkey , Elfatih Elzein , Robert H. Jiang , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Ruben Martinez , Eric Q. Parkhill , Thao Perry , Jeff Zablocki , Chandrasekar Venkataramani , Michael Graupe , Juan Guerrero
IPC: A61K31/553 , C07D267/14 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D413/04 , C07D413/14 , C07D471/12 , C07D487/04 , C07D498/04 , C07D413/12
CPC classification number: C07D498/04 , C07D267/14 , C07D413/04 , C07D413/12 , C07D413/14
Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Y, Z, n, R1 and R3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
-
公开(公告)号：US20150239904A1
公开(公告)日：2015-08-27
申请号：US14630519
申请日：2015-02-24
Applicant: GILEAD SCIENCES, INC.
Inventor： Britton Kenneth Corkey , Elfatih Elzein , Robert H. Jiang , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Ruben Martinez , Eric Q. Parkhill , Thao Perry , Jeff Zablocki , Chandrasekar Venkataramani , Michael Graupe , Juan Guerrero
IPC: C07D498/04 , C07D413/14 , C07D413/12 , C07D267/14 , C07D413/04
CPC classification number: C07D498/04 , C07D267/14 , C07D413/04 , C07D413/12 , C07D413/14
Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Y, Z, n, R1 and R3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
Abstract translation: 本公开涉及作为钠通道抑制剂的化合物及其用于治疗各种疾病状态（包括心血管疾病和糖尿病）的用途。 在具体实施方案中，化合物的结构由式I给出：其中Y，Z，n，R 1和R 3如本文所述，涉及化合物的制备和使用方法以及含有该化合物的药物组合物。
-
公开(公告)号：US09598435B2
公开(公告)日：2017-03-21
申请号：US14872787
申请日：2015-10-01
Applicant: Gilead Sciences, Inc.
Inventor： Britton Kenneth Corkey , Elfatih Elzein , Michael Graupe , Juan Guerrero , Robert H. Jiang , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Ruben Martinez , Eric Q. Parkhill , Thao Perry , Chandrasekar Venkataramani , Jeff Zablocki
IPC: C07D267/08 , C07D498/04 , A61K31/553 , A61K31/5513 , C07D243/24 , C07D267/14 , C07D291/08 , C07D403/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D419/06 , C07D471/04 , C07D487/04 , C07D243/14 , C07B59/00 , C07D413/04 , C07D417/14
CPC classification number: C07D413/06 , A61K31/5513 , A61K31/553 , C07B59/002 , C07B2200/05 , C07D243/14 , C07D243/24 , C07D267/08 , C07D267/14 , C07D291/08 , C07D403/06 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14 , C07D419/06 , C07D471/04 , C07D487/04 , C07D498/04
Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z1, Z2, Z3, Z4, X, Y, R2, R3 and R4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
-
公开(公告)号：US20160362421A1
公开(公告)日：2016-12-15
申请号：US15188701
申请日：2016-06-21
Applicant: Gilead Sciences, Inc.
Inventor： Britton Kenneth Corkey , Elfatih Elzein , Michael Graupe , Juan Guerrero , Robert H. Jiang , Rao V. Kalla , Tetsuya Kobayashi , Dmitry Koltun , Xiaofen Li , Ruben Martinez , Gregory Notte , Eric Q. Parkhill , Thao Perry , Chandrasekar Venkataramani , Jeff Zablocki
IPC: C07D498/10 , C07D401/04 , C07D403/04 , C07D413/06 , C07D403/06 , C07D413/14 , C07D417/06 , C07D403/12 , C07D401/12 , C07D401/14 , C07D237/32 , C07D417/12 , C07D401/06 , C07D265/22 , C07D279/08 , C07D217/26 , C07D405/12 , C07D253/08
CPC classification number: C07D498/10 , C07D217/26 , C07D237/32 , C07D239/88 , C07D239/90 , C07D253/08 , C07D263/58 , C07D265/22 , C07D279/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D498/04
Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R1, X1, X2, Y and R2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
Abstract translation: 其中Q，R 1，X 1，X 2，Y和R 2如本文所述，用于制备和使用化合物的方法以及含有该化合物的药物组合物。
-
公开(公告)号：US20160347744A1
公开(公告)日：2016-12-01
申请号：US15152231
申请日：2016-05-11
Applicant: Gilead Sciences, Inc.
Inventor： Britton Kenneth Corkey , Elfatih Elzein , Michael Graupe , Juan Guerrero , Robert H. Jiang , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Ruben Martinez , Eric Q. Parkhill , Thao Perry , Chandrasekar Venkataramani , Jeff Zablocki
IPC: C07D413/06 , A61K31/553
CPC classification number: C07D413/06 , A61K31/5513 , A61K31/553 , C07B59/002 , C07B2200/05 , C07D243/14 , C07D243/24 , C07D267/08 , C07D267/14 , C07D291/08 , C07D403/06 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14 , C07D419/06 , C07D471/04 , C07D487/04 , C07D498/04
Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z1, Z2, Z3, Z4, X, Y, R2, R3 and R4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
Abstract translation: 其中Z 1，Z 2，Z 3，Z 4，X，Y，R 2，R 3和R 4如本文所述，用于制备和使用化合物的方法和含有该化合物的药物组合物。
-
公开(公告)号：US20130184255A1
公开(公告)日：2013-07-18
申请号：US13789469
申请日：2013-03-07
Applicant: Gilead Sciences, Inc.
Inventor： Britton Kenneth Corkey , Elfatih Elzein , Robert H. Jiang , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Ruben Martinez , Eric Q. Parkhill , Thao Perry , Jeff Zablocki , Chandrasekar Venkataramani , Michael Graupe , Juan Guerrero
IPC: C07D413/06 , C07D471/04
CPC classification number: C07D413/06 , A61K31/5513 , A61K31/553 , C07B59/002 , C07B2200/05 , C07D243/14 , C07D243/24 , C07D267/08 , C07D267/14 , C07D291/08 , C07D403/06 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14 , C07D419/06 , C07D471/04 , C07D487/04 , C07D498/04
Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z1, Z2, Z3, Z4, X, Y, R2, R3 and R4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
Abstract translation: 本公开涉及作为钠通道抑制剂的化合物及其用于治疗各种疾病状态（包括心血管疾病和糖尿病）的用途。 在具体实施方案中，化合物的结构由式I给出：其中Z 1，Z 2，Z 3，Z 4，X，Y，R 2，R 3和R 4如本文所述，用于制备和使用该化合物的方法， 含有该组合物的药物组合物。
-
公开(公告)号：US20240182476A1
公开(公告)日：2024-06-06
申请号：US18450646
申请日：2023-08-16
Applicant: GILEAD SCIENCES, INC. , CARNA BIOSCIENCES, INC.
Inventor： Masaaki Sawa , Mai Arai , Ryoko Nakai , Hirokazu Matsumoto , Catherine Pugh , Eric Hu , Juan Guerrero , Jesse Jacobsen , Jonathan William Medley , Jie Xu , Latesh Lad , Leena Patel , Michael Graupe , Qingming Zhu , Stephen Holmbo , Tetsuya Kobayashi , Will Watkins , Yasamin Moazami , Suet C. Yeung , Julian A. Codelli , Heath A. Weaver
IPC: C07D487/04 , A61K31/395 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/55 , A61K31/553 , A61K31/695 , A61K31/704 , A61K31/7068 , A61K35/15 , A61K35/17 , A61K39/395 , A61K45/06 , C07D519/00 , C07F7/18
CPC classification number: C07D487/04 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/55 , A61K31/553 , A61K31/5545 , A61K31/695 , A61K31/704 , A61K31/7068 , A61K35/15 , A61K35/17 , A61K39/3955 , A61K45/06 , C07D519/00 , C07F7/1804
Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
-
公开(公告)号：US09193694B2
公开(公告)日：2015-11-24
申请号：US14038646
申请日：2013-09-26
Applicant: Gilead Sciences, Inc.
Inventor： Britton Kenneth Corkey , Elfatih Elzein , Robert H. Jiang , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Ruben Martinez , Eric Q. Parkhill , Thao Perry , Jeff Zablocki , Chandrasekar Venkataramani , Michael Graupe , Juan Guerrero
IPC: C07D243/14 , A61K31/5513 , C07D243/24 , C07D267/14 , C07D291/08 , C07D403/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D419/06 , C07D471/04 , C07D487/04 , C07D498/04
CPC classification number: C07D413/06 , A61K31/5513 , A61K31/553 , C07B59/002 , C07B2200/05 , C07D243/14 , C07D243/24 , C07D267/08 , C07D267/14 , C07D291/08 , C07D403/06 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14 , C07D419/06 , C07D471/04 , C07D487/04 , C07D498/04
Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z1, Z2, Z3, Z4, X, Y, R2, R3 and R4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
Abstract translation: 本公开涉及作为钠通道抑制剂的化合物及其用于治疗各种疾病状态（包括心血管疾病和糖尿病）的用途。 在具体实施方案中，化合物的结构由式I给出：其中Z 1，Z 2，Z 3，Z 4，X，Y，R 2，R 3和R 4如本文所述，用于制备和使用该化合物的方法， 含有该组合物的药物组合物。
-
公开(公告)号：US20240400568A1
公开(公告)日：2024-12-05
申请号：US18645837
申请日：2024-04-25
Applicant: GILEAD SCIENCES, INC. , CARNA BIOSCIENCES, INC.
Inventor： Masaaki Sawa , Mai Arai , Ryoko Nakai , Hirokazu Matsumoto , Catherine Pugh , Eric Hu , Juan Guerrero , Jesse Jacobsen , Jonathan William Medley , Jie Xu , Latesh Lad , Leena Patel , Michael Graupe , Qingming Zhu , Stephen Holmbo , Tetsuya Kobayashi , Will Watkins , Yasamin Moazami , Suet C. Yeung , Julian A. Codelli , Heath A. Weaver
IPC: C07D487/04 , A61K31/395 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/55 , A61K31/553 , A61K31/695 , A61K31/704 , A61K31/7068 , A61K35/15 , A61K35/17 , A61K39/395 , A61K45/06 , C07D519/00 , C07F7/18
Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
-
公开(公告)号：US09682998B2
公开(公告)日：2017-06-20
申请号：US15188701
申请日：2016-06-21
Applicant: Gilead Sciences, Inc.
Inventor： Britton Kenneth Corkey , Elfatih Elzein , Michael Graupe , Juan Guerrero , Robert H. Jiang , Rao V. Kalla , Tetsuya Kobayashi , Dmitry Koltun , Xiaofen Li , Ruben Martinez , Gregory Notte , Eric Q. Parkhill , Thao Perry , Chandrasekar Venkataramani , Jeff Zablocki
IPC: C07D255/04 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/14 , C07D401/14 , A61K31/53 , A61P25/08 , C07D498/10 , C07D498/04 , C07D263/58 , C07D237/32 , C07D239/88 , C07D239/90 , C07D253/08 , C07D265/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , C07D217/26 , C07D413/12 , C07D279/08 , C07D417/12
CPC classification number: C07D498/10 , C07D217/26 , C07D237/32 , C07D239/88 , C07D239/90 , C07D253/08 , C07D263/58 , C07D265/22 , C07D279/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D498/04
Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R1, X1, X2, Y and R2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
